NEW YORK – Personal Genome Diagnostics and Mayo Clinic have launched a project to evaluate the firm's next-generation sequencing (NGS) tissue and liquid biopsy technology with the goal of helping the hospital improve cancer treatment by identifying effective therapy options and improving monitoring of patient response to therapy.
Through Mayo Clinic Pact, PGDx Hopes to Show Clinical Utility for NGS Tissue, Liquid Biopsy Assays
Premium
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.